FDA accepts Alvotech/Teva second interchangeable Entyvio biosimilar application

The FDA accepted an aBLA for AVT80, a subcutaneous formulation of Alvotech and Teva's proposed interchangeable vedolizumab biosimilar, marking their second biosimilar candidate for Takeda's $3.89B drug.